Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGESKILL
- Development stage
- Preclinical
- Lead developer
- Bioscience Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
AGESKILL is an autologous cell therapy consisting of laboratory-expanded adipose-derived mesenchymal stem cells (MSCs) administered via intravenous infusion. Developed by the Bioscience Institute, the therapy is designed as a systemic anti-aging treatment to counteract biological aging, reduce systemic inflammation, support mitochondrial efficiency, and improve organ and cognitive function. The patient's own stem cells are harvested via liposuction, isolated, expanded in a GMP-certified laboratory, and then delivered systemically to promote tissue regeneration and cellular resilience.
- Brand names
- AGESKILL
- Other names
- AGESKILL Anti-Aging IV TherapyAnti-Aging IV Therapy
Beyond the preview
Go deeper on AGESKILL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGESKILL.